These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 32449983)
1. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Chan HT; Nagayama S; Chin YM; Otaki M; Hayashi R; Kiyotani K; Fukunaga Y; Ueno M; Nakamura Y; Low SK Mol Oncol; 2020 Aug; 14(8):1719-1730. PubMed ID: 32449983 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: A Chinese pan-cancer cohort. Xu E; Su K; Zhou Y; Gong L; Xuan Y; Liao M; Cao J; Li Y; Lu Y; Zhao Y; Chen F J Cell Mol Med; 2021 Nov; 25(21):10279-10290. PubMed ID: 34658138 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer. Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000 [TBL] [Abstract][Full Text] [Related]
4. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Hu Y; Ulrich BC; Supplee J; Kuang Y; Lizotte PH; Feeney NB; Guibert NM; Awad MM; Wong KK; Jänne PA; Paweletz CP; Oxnard GR Clin Cancer Res; 2018 Sep; 24(18):4437-4443. PubMed ID: 29567812 [No Abstract] [Full Text] [Related]
5. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. Okamura R; Piccioni DE; Boichard A; Lee S; Jimenez RE; Sicklick JK; Kato S; Kurzrock R Int J Cancer; 2021 Jun; 148(11):2839-2847. PubMed ID: 33497479 [TBL] [Abstract][Full Text] [Related]
6. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays. Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244 [TBL] [Abstract][Full Text] [Related]
7. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187 [TBL] [Abstract][Full Text] [Related]
8. Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Chan HT; Chin YM; Nakamura Y; Low SK Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823942 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer. Lee KS; Lee CK; Kwon SS; Kwon WS; Park S; Lee ST; Choi JR; Rha SY; Shin S Clin Chem Lab Med; 2024 Jan; 62(1):178-186. PubMed ID: 37435889 [TBL] [Abstract][Full Text] [Related]
10. Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis. Suehara Y; Sakata-Yanagimoto M; Hattori K; Kusakabe M; Nanmoku T; Sato T; Noguchi M; Chiba S Cancer Sci; 2019 Oct; 110(10):3375-3381. PubMed ID: 31436356 [TBL] [Abstract][Full Text] [Related]
11. Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Fairchild L; Whalen J; D'Aco K; Wu J; Gustafson CB; Solovieff N; Su F; Leary RJ; Campbell CD; Balbin OA Sci Transl Med; 2023 Mar; 15(689):eabm8729. PubMed ID: 36989374 [TBL] [Abstract][Full Text] [Related]
12. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595 [TBL] [Abstract][Full Text] [Related]
13. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850 [TBL] [Abstract][Full Text] [Related]
14. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920 [TBL] [Abstract][Full Text] [Related]
15. Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms. Bádon ES; Mokánszki A; Mónus A; András C; Méhes G Mol Cell Probes; 2023 Feb; 67():101891. PubMed ID: 36586518 [TBL] [Abstract][Full Text] [Related]
16. Utility of plasma cell-free DNA for Gutierrez-Rodrigues F; Beerman I; Groarke EM; Patel BA; Spitofsky N; Dillon LW; Raffo DQ; Hourigan CS; Kajigaya S; Ferrucci L; Young NS Haematologica; 2022 Aug; 107(8):1815-1826. PubMed ID: 34587721 [TBL] [Abstract][Full Text] [Related]
17. Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy? Pittella-Silva F; Chin YM; Chan HT; Nagayama S; Miyauchi E; Low SK; Nakamura Y Clin Chem; 2020 Jul; 66(7):946-957. PubMed ID: 32516802 [TBL] [Abstract][Full Text] [Related]
18. Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients. Palande V; Raviv Shay D; Frenkel-Morgenstern M J Vis Exp; 2020 Sep; (163):. PubMed ID: 32986022 [TBL] [Abstract][Full Text] [Related]
19. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]